Peripheral nervous system disease is a component of systemic lupus erythematosus disease activity and has a significant negative impact on health-related quality of life.
A Prescription Drug User Fee Act (PDUFA) target date of July 13, 2020 has been assigned to the application.
Higher systolic blood pressure and decreased low-density lipoprotein are associated with increased risk for peripheral neuropathy in patients with type 2 diabetes.
Although the prevalence of distal sensory peripheral neuropathy decreased following initiation of cART in people living with in resource-limiting settings, better strategies are needed.
Amphiphysin-IgG-mediated autoimmunity is an important clinical entity characterized by neuropathy.
Recognition of the wide phenotype spectrum in immune checkpoint inhibitor-related neuropathy and prompt management with corticosteroids may lead to favorable outcomes.
Perineural injection of platelet-rich plasma may improve pain and numbness associated with diabetic peripheral neuropathy, and enhance peripheral nerve function.
The prevalence of neuropathic-like pain was found to be high in patients with psoriatic arthritis, a condition that may be associated with higher disease activity and fibromyalgia.
The presence of neuropathic pain was identified as a risk factor for low physical and mental quality of life in middle-aged and elderly patients.
Researchers found a substantial cohort of adults with diabetic peripheral neuropathy in the United States with high financial and social costs.